Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma

• Status: Recruiting
• Trial end date: 2024-05-31
• Target enrollment: 0
• Participant gender: All

Summary

Observe the best dose, efficacy and adverse reactions of BAd in the treatment of relapsed and refractory multiple myeloma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Liao Aijun
• Treatments: Bendamustine Hydrochloride; Dexamethasone; Doxorubicin; Liposomal doxorubicin

Criteria

Inclusion Criteria:

1. Age ≥ 18 years old

2. ≥1 line relapsed or refractory multiple myeloma

3. Alanine aminotransferase is less than 2.5 times the upper limit of normal, and total bilirubin is less than 1.5 times the upper limit of normal

4. Creatinine clearance rate>40ml/min

5. No serious heart disease

Exclusion Criteria:

1. Untreated multiple myeloma patients

2. Pregnant or lactating women

3. Alanine aminotransferase is more than 2.5 times the upper limit of normal, and total bilirubin is more than 1.5 times the upper limit of normal

4. Creatinine clearance rate ≤40ml/min

5. Severe heart disease